Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemtabrutinib vs Chemoimmunotherapy in Previously Untreated CLL/SLL Without TP53 Aberrations
NCT05624554Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2023
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, open-label trial of nemtabrutinib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 arms), sponsored by Merck & Co. Primary endpoint: Progression-Free Survival at 49 months. Started Mar 2023; status: active, not recruiting.
02
Drugs
nemtabrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT05624554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05624554.